Rivaroxaban superior to enoxaparin in preventing VTE after knee arthroplasty

May 21st, 2009 by admin

Results from the Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism 4 (RECORD4) trial published in Lancet demonstrated that rivaroxaban 10 mg once daily is superior to subcutaneous (SC) enoxaparin in preventing venous thromboembolism (VTE) after total knee arthroplasty.

More: continued here

Leave a Reply